Stay updated on Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Updated eligibility criteria now allow concurrent hormonal or anti-HER2 therapy if brain metastases progress; MRI criteria were revised to require at least 2 untreated measurable brain metastases (≥3 mm) within two weeks before treatment, and prior subtotal resection is permitted if residual disease <4 cm.
    Difference
    0.5%
    Check dated 2026-04-02T05:42:46.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    Site revision history updated: added v3.5.0 and removed v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-18T20:21:11.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T18:20:48.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed on the page. The funding-status notice corresponding to Revision: v3.4.1 has been removed.
    Difference
    0.4%
    Check dated 2026-02-11T05:20:21.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding at the top of the page and updated the revision to v3.4.1. The previous revision tag v3.4.0 was removed.
    Difference
    0.4%
    Check dated 2026-02-04T03:56:22.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page now includes a Show glossary option and updates footer/metadata labels to 'Last Update Submitted that Met QC Criteria,' 'No FEAR Act Data,' and 'Revision: v3.4.0' (replacing the previous 'No FEAR Act data' and 'Revision: v3.3.4'). This change is limited to UI/metadata text and does not affect the study content.
    Difference
    0.2%
    Check dated 2026-01-28T00:47:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.